Latest Medicinal Cannabis Market News

Page 1 of 3
Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.
Ada Torres
Ada Torres
1 Apr 2026
Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.
Ada Torres
Ada Torres
17 Mar 2026
Cann Group Limited has raised $750,000 through a convertible note agreement with Obsidian Global, aiming to strengthen its working capital and move towards EBITDA positivity.
Ada Torres
Ada Torres
16 Mar 2026
ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.
Ada Torres
Ada Torres
27 Feb 2026
Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.
Ada Torres
Ada Torres
25 Feb 2026
ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.
Ada Torres
Ada Torres
11 Feb 2026
Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.
Ada Torres
Ada Torres
5 Feb 2026
Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.
Ada Torres
Ada Torres
3 Feb 2026
Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.
Ada Torres
Ada Torres
30 Jan 2026
Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.
Ada Torres
Ada Torres
28 Jan 2026
Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.
Ada Torres
Ada Torres
28 Jan 2026
Little Green Pharma Ltd has agreed to acquire Cannatrek Ltd in a transformational merger that will create a leading vertically integrated medicinal cannabis group across Australia and Europe. The deal combines cultivation, manufacturing, distribution, clinics, and digital health platforms under one roof, positioning the combined entity for accelerated growth.
Ada Torres
Ada Torres
14 Jan 2026